CBL-514

CBL-514
Clinical data
Other namesCBL514; CBL-514D; CBL514D
Routes of
administration		Subcutaneous injection
Drug classDYRK1B inhibitor

CBL-514 is a DYRK1B inhibitor and "lipolysis drug" which is under development for the treatment of subcutaneous fat disorders such as Dercum's disease (painful lipomas), adiposis dolorosa, cellulite, and obesity. It is taken by subcutaneous injection.

The drug works by inhibiting the cell survival kinase DYRK1B, which in turn upregulates the apoptosis mediators caspase 3 and Bax/Bcl-2 to dose-dependently and selectively promote adipocyte apoptosis and lipolysis in vitro and in vivo. CBL-514 has been found to reduce both subcutaneous and visceral fat in humans. It is said to be a novel first-in-class drug.

CBL-514 is under development by Caliway Biopharmaceuticals. As of August 2026, it is in phase 3 clinical trials for subcutaneous fat disorders and is in phase 2 trials for adiposis dolorosa, cellulite, and obesity. The chemical structure of CBL-514 does not yet appear to have been released. However, the drug has been described as being a stabilized combination of resveratrol and curcumin.

References

  1. 1 2 3 4 5 6 "CBL 514". AdisInsight. Springer Nature. Retrieved 4 October 2026.
  2. 1 2 3 4 5 6 "New weight-loss injection targets fat cells: CBL-514 selectively induces apoptosis of fat cells", Medical Xpress, 2 October 2026, retrieved 4 October 2026
  3. 1 2 Idris YA, Janis JE (July 2026). "Dercum's Disease: A Practical Review of Existing and Novel Therapies". Plastic and Reconstructive Surgery. Global Open. 14 (7) e7907. doi:10.1097/GOX.0000000000007907. PMC 13391129. PMID 42488923.
  4. ↑ Carrion K, Salingaros S, Bernal C, Barger BT, Lipman KJ, How-Volkman C, et al. (September 2026). "A Systematic Review of Injectable Lipolytic Agents for Nonsubmental Fat Reduction". Plastic and Reconstructive Surgery. 158 (3): 414–423. doi:10.1097/PRS.0000000000012648. PMID 41296813.
  5. 1 2 Goodman GJ, Ho WW, Chang KJ, Ling YF, Sheu AY (October 2022). "Efficacy of a Novel Injection Lipolysis to Induce Targeted Adipocyte Apoptosis: A Randomized, Phase IIa Study of CBL-514 Injection on Abdominal Subcutaneous Fat Reduction". Aesthetic Surgery Journal. 42 (11): NP662–NP674. doi:10.1093/asj/sjac162. PMC 9384315. PMID 35709509. CBL-514 (Caliway Biopharmaceuticals, New Taipei City, Taiwan) is an injection lipolysis drug. CBL-514 induced adipocyte apoptosis and lipolysis in vitro and promoted adipose cell apoptosis and reduced subcutaneous adiposity in targeted areas in animal studies. Our nonclinical studies showed that CBL-514 inhibits the cell survival kinase DYRK1b; upregulates the apoptosis mediators caspase 3 and Bax/Bcl-2; and induces dose-dependent adipocyte apoptosis in vivo and in vitro (Caliway Biopharmaceuticals, unpublished confidential reports).31
  6. 1 2 3 "Delving into the Latest Updates on Resveratrol/Curcumin with Synapse". Synapse. 22 September 2026. Retrieved 4 October 2026.
  7. ↑ "280278-ABDOMINAL SUBCUTANEOUS FAT Canadian clinical trial search portal". Trouver un essai clinique au Canada. 25 January 2026. Retrieved 4 October 2026.